文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

结肠癌根治术后的真实世界生存情况:一项单机构回顾性分析。

Real-world survival of colon cancer after radical surgery: A single-institutional retrospective analysis.

作者信息

Pang Xiangyi, Xu Benjie, Lian Jie, Wang Ren, Wang Xin, Shao Jiayue, Tang Shuli, Lu Haibo

机构信息

Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, China.

出版信息

Front Oncol. 2022 Sep 16;12:914076. doi: 10.3389/fonc.2022.914076. eCollection 2022.


DOI:10.3389/fonc.2022.914076
PMID:36185216
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9525022/
Abstract

The survival rate for colon cancer after radical surgery has been the focus of extensive debate. To assess the postoperative survival and prognostic factors for overall survival (OS), we collected clinicopathological information for 2,655 patients. The survival time and potential risk factors for OS were analyzed by using Kaplan-Meier curves, Cox proportional hazards models, best subset regression (BSR), and least absolute shrinkage and selection operator (LASSO). The 5-year survival rates of stage I-IV colon cancer were 96.6%, 88.7%, 69.9%, and 34.3%, respectively. Adjuvant chemotherapy improved the survival rate (90.4% vs. 82.4%, with versus without adjuvant chemotherapy, respectively) in stage II patients with high-risk factors. Elevated preoperative carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were significantly associated with worse OS compared with patients without these elevations. Less than 12 versus more than 12 harvested lymph nodes (LNs) affected prognosis (84.6% vs. 89.7%, respectively). Regarding the lymph node ratio (LNR), the 5-year OS rate was 89.2%, 71.5%, 55.8%, and 34.5% in patients with LNR values of 0, 0.3, 0.3-0.7, and >0.7, respectively. We constructed a nomogram comprising the independent factors associated with survival to better predict prognosis. On the basis of these findings, we propose that stage II colon cancer patients without high-risk factors and with both elevated preoperative CEA and CA199 should receive adjuvant therapy. Furthermore, the LNR could complement TNM staging in patients with <12 harvested LNs. Our nomogram might be useful as a new prognosis prediction system for colon cancer patients.

摘要

根治性手术后结肠癌的生存率一直是广泛争论的焦点。为了评估术后生存率及总生存(OS)的预后因素,我们收集了2655例患者的临床病理信息。采用Kaplan-Meier曲线、Cox比例风险模型、最佳子集回归(BSR)和最小绝对收缩和选择算子(LASSO)分析了OS的生存时间和潜在风险因素。I-IV期结肠癌的5年生存率分别为96.6%、88.7%、69.9%和34.3%。辅助化疗提高了具有高危因素的II期患者的生存率(分别为90.4%和82.4%,有辅助化疗与无辅助化疗)。与未出现这些升高的患者相比,术前癌胚抗原(CEA)和糖类抗原19-9(CA19-9)升高与更差的OS显著相关。少于12枚与多于12枚的清扫淋巴结(LNs)影响预后(分别为84.6%和89.7%)。关于淋巴结比率(LNR),LNR值为0、0.3、0.3-0.7和>0.7的患者的5年OS率分别为89.2%、71.5%、55.8%和34.5%。我们构建了一个包含与生存相关的独立因素的列线图,以更好地预测预后。基于这些发现,我们建议无高危因素且术前CEA和CA199均升高的II期结肠癌患者应接受辅助治疗。此外,LNR可补充清扫LNs少于12枚患者的TNM分期。我们的列线图可能作为一种新的结肠癌患者预后预测系统有用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/dc20b041c578/fonc-12-914076-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/b99b69248e6f/fonc-12-914076-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/78ba155d642d/fonc-12-914076-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/183497cdc1b1/fonc-12-914076-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/58fd06344929/fonc-12-914076-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/8a5309de5ee8/fonc-12-914076-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/dc20b041c578/fonc-12-914076-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/b99b69248e6f/fonc-12-914076-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/78ba155d642d/fonc-12-914076-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/183497cdc1b1/fonc-12-914076-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/58fd06344929/fonc-12-914076-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/8a5309de5ee8/fonc-12-914076-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3649/9525022/dc20b041c578/fonc-12-914076-g006.jpg

相似文献

[1]
Real-world survival of colon cancer after radical surgery: A single-institutional retrospective analysis.

Front Oncol. 2022-9-16

[2]
Dynamic monitoring of serum CEA and CA19-9 predicts the prognosis of postoperative stage II colon cancer.

Eur J Surg Oncol. 2023-12

[3]
[Predictive value of preoperative detection of CEA and CA199 for prognosis in patients with stage II-III colorectal cancer].

Zhonghua Wei Chang Wai Ke Za Zhi. 2015-9

[4]
Positive lymph node ratio predicts adverse prognosis for patients with lymph nodes metastatic hypopharyngeal squamous cell carcinoma after primary surgery.

Transl Cancer Res. 2022-3

[5]
[Prognostic value and initial exploratory research on TNM staging method of tumor deposits in stage III colon cancer].

Zhonghua Wei Chang Wai Ke Za Zhi. 2019-12-25

[6]
[Analysis of prognostic factors after radical resection in 628 patients with stage II or III colon cancer].

Zhonghua Zhong Liu Za Zhi. 2013-3

[7]
Assessment of Clinicopathological Characteristics and Development of an Individualized Prognostic Model for Patients With Hepatoid Adenocarcinoma of the Stomach.

JAMA Netw Open. 2021-10-1

[8]
Evaluation on prognostic efficacy of lymph nodes ratio (LNR) and log odds of positive lymph nodes (LODDS) in complicated colon cancer: the first study in emergency surgery.

World J Surg Oncol. 2018-9-13

[9]
[The relationship between the index of lymph node metastasis and the prognosis of pancreatic cancer patients after R0 resection].

Zhonghua Zhong Liu Za Zhi. 2020-6-23

[10]
A Novel Inflammatory-Nutritional Prognostic Scoring System for Stage III Gastric Cancer Patients With Radical Gastrectomy Followed by Adjuvant Chemotherapy.

Front Oncol. 2021-6-14

引用本文的文献

[1]
Predictive value of the systemic inflammation grade for overall survival in patients with colorectal cancer after surgery: outperforming NLR and mGPS.

Front Oncol. 2025-6-17

[2]
Cost effectiveness analysis of three colorectal cancer screening modalities in Kuwait.

Sci Rep. 2025-3-1

[3]
Lipid levels and insulin resistance markers in patients with colorectal cancer: Propensity score matching analysis.

World J Gastrointest Oncol. 2025-1-15

[4]
Impact of gut microbiota and its metabolites on immunometabolism in colorectal cancer.

Immunometabolism (Cobham). 2024-11-28

[5]
Prognostic value of a nomogram model for postoperative liver metastasis of colon cancer.

World J Gastrointest Surg. 2024-4-27

[6]
Identification of colon cancer subtypes based on multi-omics data-construction of methylation markers for immunotherapy.

Front Oncol. 2024-1-22

[7]
Three-dimensional laparoscopic surgery for colorectal cancer: A 2-year follow-up study at Hue Central Hospital.

Surg Open Sci. 2023-12-31

[8]
Survival rate of colorectal cancer in China: A systematic review and meta-analysis.

Front Oncol. 2023-3-3

[9]
Substrate Type and Concentration Differently Affect Colon Cancer Cells Ultrastructural Morphology, EMT Markers, and Matrix Degrading Enzymes.

Biomolecules. 2022-11-30

本文引用的文献

[1]
Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).

J Clin Oncol. 2022-3-1

[2]
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.

J Clin Oncol. 2022-3-10

[3]
A Clinicopathological Feature-Based Nomogram for Predicting the Likelihood of D3 Lymph Node Metastasis in Right-Sided Colon Cancer Patients.

Dis Colon Rectum. 2023-1-1

[4]
Predictive risk-score model for selection of patients with high-risk stage II colon cancer for adjuvant systemic therapy.

Surgery. 2022-6

[5]
How I treat stage II colon cancer patients.

ESMO Open. 2021-8

[6]
Accurate Prediction of Prognosis by Integrating Clinical and Molecular Characteristics in Colon Cancer.

Front Cell Dev Biol. 2021-5-21

[7]
A Novel Prognostic Model and Practical Nomogram for Predicting the Outcomes of Colorectal Cancer: Based on Tumor Biomarkers and Log Odds of Positive Lymph Node Scheme.

Front Oncol. 2021-4-16

[8]
Colorectal cancer burden and trends: Comparison between China and major burden countries in the world.

Chin J Cancer Res. 2021-2-28

[9]
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021-5

[10]
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.

J Clin Oncol. 2021-2-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索